Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
1yexBrtrssntrb4U
Listen
